Your browser doesn't support javascript.
loading
PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity.
Carnevalli, Larissa S; Sinclair, Charles; Taylor, Molly A; Gutierrez, Pablo Morentin; Langdon, Sophie; Coenen-Stass, Anna M L; Mooney, Lorraine; Hughes, Adina; Jarvis, Laura; Staniszewska, Anna; Crafter, Claire; Sidders, Ben; Hardaker, Elizabeth; Hudson, Kevin; Barry, Simon T.
Afiliação
  • Carnevalli LS; Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK. Larissa.Carnevalli@astrazeneca.com.
  • Sinclair C; Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK.
  • Taylor MA; Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK.
  • Gutierrez PM; Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK.
  • Langdon S; Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK.
  • Coenen-Stass AML; Present Address: University of Birmingham, B15 2TT, Birmingham, UK.
  • Mooney L; Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK.
  • Hughes A; Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Alderley Park, Alderley Edge, Macclesfield, SK10 4TG, UK.
  • Jarvis L; Present Address: Alderley Park Limited, Preclinical Services, Alderley Park, Macclesfield, SK10 4TG, UK.
  • Staniszewska A; Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK.
  • Crafter C; Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK.
  • Sidders B; Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK.
  • Hardaker E; Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK.
  • Hudson K; Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK.
  • Barry ST; Bioscience, Oncology, IMED Biotech Unit AstraZeneca, Francis Crick Ave, Cambridge, CB2 0SL, UK.
J Immunother Cancer ; 6(1): 158, 2018 12 27.
Article em En | MEDLINE | ID: mdl-30587236
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos T CD8-Positivos / Inibidores de Proteínas Quinases / Imunomodulação / Classe I de Fosfatidilinositol 3-Quinases / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos T CD8-Positivos / Inibidores de Proteínas Quinases / Imunomodulação / Classe I de Fosfatidilinositol 3-Quinases / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article